Dr Miguel Martin speaks to ecancer at SABCS 2018 about the randomised, phase II GEICAM/CIBOMA trial, looking at patients with early-stage triple-negative breast cancer being treated with the chemotherapy agent capecitabine following surgery and standard chemotherapy.
He says the results of the study indicated that treating these patients with capecitabine did not significantly improve their outcomes, however elaborates on potential reasons for the lack of statistical significance.
Dr Martin also elaborates on some unexpected results from the trial, and what the next steps may be to better understand the results of the trial.
Watch his press conference here.
Read more about this work here.